Evidence map›Paper›PMID 37762029›Full record

ArticleInternational journal of molecular sciences2023

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly.

Daniela Dalla Gasperina, Giovanni Veronesi, Carlo M Castelletti, Stefania Varchetta, Sabrina Ottolini, Dalila Mele, Giuseppe Ferrari, Amruth K B Shaik, Fabrizio Celesti, Francesco Dentali and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Daniela Dalla GasperinaDepartment of Medicine and Technological Innovation, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy.ORCID 0000-0002-1187-6222
Giovanni VeronesiResearch Centre in Epidemiology and Preventive Medicine (EPIMED), Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.ORCID 0000-0002-4119-6615
Carlo M CastellettiMolina's Foundation, 21100 Varese, Italy.
Stefania VarchettaClinical Immunology-Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.ORCID 0000-0002-0289-2896
Sabrina OttoliniDepartment of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy.
Dalila MeleMicrobiology and Molecular Virology Unit, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy.ORCID 0000-0002-5217-2766
Giuseppe FerrariMolina's Foundation, 21100 Varese, Italy.
Amruth K B ShaikLaboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.
Fabrizio CelestiCenter for Immuno-Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
Francesco DentaliDepartment of Medicine and Surgery, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy.
Roberto S AccollaLaboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.
Greta ForlaniLaboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.ORCID 0000-0003-1987-7761
University of Insubria · ITPoliclinico San Matteo Fondazione · ITUniversity of Pavia · ITUniversity of Siena · IT

Funding

FONDAZIONE MOLINA NA
6 · The paper itself

Abstract

Although the safety and efficacy of COVID-19 vaccines in older people are critical to their success, little is known about their immunogenicity among elderly residents of long-term care facilities (LTCFs). A single-center prospective cohort study was conducted: a total IgG antibody titer, neutralizing antibodies against Wild-type, Delta Plus, and Omicron BA.2 variants and T cell response, were measured eight months after the second dose of BNT162b2 vaccine (T0) and at least 15 days after the booster (T1). Forty-nine LTCF residents, with a median age of 84.8 ± 10.6 years, were enrolled. Previous COVID-19 infection was documented in 42.9% of the subjects one year before T0. At T1, the IgG titers increased up to 10-fold. This ratio was lower in the subjects with previous COVID-19 infection. At T1, IgG levels were similar in both groups. The neutralizing activity against Omicron BA.2 was significantly lower (65%) than that measured against Wild-type and Delta Plus (90%). A significant increase of T cell-specific immune response was observed after the booster. Frailty, older age, sex, cognitive impairment, and comorbidities did not affect antibody titers or T cell response. In the elderly sample analyzed, the BNT162b2 mRNA COVID-19 vaccine produced immunogenicity regardless of frailty.

Indexed as

COVID-19FrailtyAgedAged, 80 and overBNT162 VaccineCOVID-19 VaccinesHumansImmunity, CellularImmunization, SecondaryImmunoglobulin GProspective StudiesBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GBNT162b2 mRNA COVID-19 vaccinecellular immunitylong-term care facilities elderly residentsneutralizing antibodiesOmicron BA.2

Identifiers

PMID37762029
PMCPMC10530943
OpenAlexW4386484160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.